Stocks to Watch: TCS, Wipro, Bandhan Bank, DMart, HDFC

0
524

The top 10 equities that will likely be scrutinised on Monday are listed below: TCS: The largest software exporter in the nation, TCS, announced a 5.2% increase in the June quarter net profit to 9,478 crore on Friday.

However, this increase was constrained by the impact of yearly salary increases and promotions, which caused operational profit margins to decline to multi-quarter lows.

However, the Tata Group company, which is the first to announce earnings in the nation’s over USD 220 billion software exports industry, claimed that it does not anticipate any negative economic effects from concerns about the recession in its core markets.

Avenue Supermarts: On Saturday, the company that owns and runs the D-Mart network of hypermarkets announced a standalone net profit of Rs. 680 crore for the first quarter of the current financial year, nearly six times more than the Rs. 115 crore figure for the same period last year.

Wipro: As India’s technology sector continues to experience a covid-induced hiring boom, Wipro Ltd is revising its employee bonuses and raises in an effort to reduce high attrition and draw in new talent.

The fourth-largest software services company in India intends to grant staff promotions on a quarterly basis—a first for the Bengaluru-based business—and raise the salaries of the majority of its employees by 10% in September, with the top achievers receiving raises of more than 15%.

Bandhan Bank: As of June 30, Bandhan Bank’s advances increased by 20% from a year earlier to reach 96,649 crore, the bank reported on Friday. By the end of the first quarter of FY23, the private sector lender’s total deposits had increased by 20% to 93,057 crore, according to Bandhan Bank‘s regulatory filing.

Monte Carlo Fashions: On Friday, the clothing company announced a 130% gain in revenue during the April–June fiscal quarter, which was aided by both price and volume increases.

“As things started to return to normal, the company had solid demand across all revenue segments during the quarter. It had outstanding first-quarter sales and significant revenue increase of over 130% in Q1 FY23 “during the business report for Q1 FY2022-23,

Monte Carlo Fashions stated Dr. Reddy’s Lab: On Friday, Dr. Reddy’s Laboratories Ltd. said that it had begun selling its generic version of the overactive bladder medication fesoterodine fumarate extended-release tablets in the US market.

According to the pharmaceutical company’s regulatory application, the launch comes after the US Food and Drug Administration (USFDA) gave its permission.

According to its Annual Report for 2021–22, Aurobindo Pharma is still focused on creating complicated and unique medicines across a variety of industries, including oncology, hormonal products, biosimilars, depot injections, and vaccines, to propel the company’s next phase of growth.

Prior to its merger with its banking subsidiary HDFC Bank, regulator PFRDA approved a revision to HDFC Ltd’s structure and ordered that services provided to the company’s NPS subscribers not be impacted.

Follow and connect with us on Facebook, LinkedIn & Twitter

LEAVE A REPLY

Please enter your comment!
Please enter your name here